Clinical trial
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
NCT00002980 · California Cancer Consortium, Other · Completed
Key facts
| NCT number | NCT00002980 |
|---|---|
| Title | Decitabine in Treating Patients With Melanoma or Other Advanced Cancer |
| Official title | A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | decitabine |
| Start date | May 1, 1997 |
| First posted | Sep 3, 2004 |
| Last update posted | Feb 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: